Online citations, reference lists, and bibliographies.
← Back to Search

Current Status Of Screening For Malignant Pleural Mesothelioma.

H. Pass, M. Carbone
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma is characterized by its association with asbestos, its long latency period, and the propensity for the diagnosis to be obtained in the later stages of the disease. Because the high-risk cohorts for mesothelioma are fairly well defined by the association with asbestos, and the exposure is usually in the workplace, it is hypothesized that early detection of the disease could (1) find patients at an earlier, more treatable stage and (2) result in prolonged survival over the present median 12 months from the start of therapy. Many studies have used standard chest X-ray to characterize changes associated with asbestos-exposed individuals, but the insensitivity of X-ray in screening patients with mesothelioma has never supported the wide-scale adaptation of such an effort. With the advent of computerized tomography, prospective trials, many of which are chiefly prevalence detection studies, have been performed and stress the importance for proper detailing by carefully qualifying suspicious changes, as well as defining the correct cohort to screen. Most recently, serum biomarkers with the potential to discriminate asbestos-exposed, non-cancer-bearing individuals from those with mesothelioma have been investigated both at single institutions and with multi-institutional-blinded trials. These markers, including soluble mesothelin-related protein, osteopontin, and megakaryocyte potentiating factor, may, in the future, be incorporated into a screening algorithm for high-risk asbestos-exposed individuals to help monitor these cohorts in a noninvasive fashion and guide the use of computerized tomography.
This paper references
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L
Latency of asbestos disease among insulation workers in the United States and Canada
I. Selikoff (1980)
10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.0.CO;2-N
Hyaluronan in serum as an indicator of progressive disease in hyaluronan‐producing malignant mesothelioma
A. Thylén (1999)
10.1111/J.1445-5994.1999.TB00777.X
Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Y. Lee (1999)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1038/nrc2068
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
M. Carbone (2007)
Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
W. Ebert (1997)
10.1002/1097-0142(19870615)59:12<2104::AID-CNCR2820591224>3.0.CO;2-I
Serum hyaluronate in malignant pleural mesothelioma
T. Frebourg (1987)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1136/oem.29.3.274
Radiological survey of men exposed to asbestos in naval dockyards
P. Harries (1972)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
10.1002/(SICI)1097-0274(199712)32:6<573::AID-AJIM1>3.0.CO;2-R
The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts.
S. Barnhart (1997)
10.1016/J.LUNGCAN.2004.10.011
Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE).
A. Wali (2005)
Asbestos Litigation Costs and Compensation: An Interim Report
S. Carroll (2002)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
Combined CA 125 and mesothe - lin levels for the diagnosis of MM
J Creaney (2007)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
Hyaluronic acid analysis and the diagnosis of pleural mesothelioma.
A. Boersma (1980)
Surviving the asbestos epidemic
N Shah (2001)
10.1056/NEJM200301023480115
Cough and bronchial responsiveness in firefighters at the World Trade Center site.
B. Hanson (2003)
10.1007/s00330-006-0426-8
Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT
M. Das (2006)
10.1016/S0169-5002(03)92469-X
Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.
M. Hedman (2003)
10.1080/01913120252959227
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
in asbestos - exposed workers
T Vierikko (2002)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1191/0748233701th112oa
Occupational exposures during the World Trade Center disaster response
K. Wallingford (2001)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1634/THEONCOLOGIST.12-10-1215
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
G. Fasola (2007)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1183/09031936.00073606
Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings
T. Vierikko (2007)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1023/A:1008845332422
Incidence of cancer among Finnish patients with asbestos-related pulmonary or pleural fibrosis
A. Karjalainen (2004)
10.1126/SCIENCE.2153315
Asbestos: scientific developments and implications for public policy.
B. Mossman (1990)
10.1001/jama.1985.03360100055006
Asbestos-related diseases.
D. G. Kern (1991)
Statement on MM in the UK
A Scherpereel (2002)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1378/CHEST.119.4.1138
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
M. Paganuzzi (2001)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
Malignant mesothelioma of 17 years' duration with high pleural fluid concentration of hyaluronate.
P. Hellström (1977)
10.1200/JCO.2008.26.15_SUPPL.11074
Evaluation of plasma osteopontin as early detection and prognostic marker in malignant pleural mesothelioma
Amanda M Beck (2008)
10.1016/j.bbrc.2009.03.042
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.
S. Ivanov (2009)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
Prognostic value of the serum tumour markers Cyfra 21 - 1 and tissue polypeptide antigen in MM
M Marukawa (1999)
Cloning and expression of the recombinant FAb fragment of monoclonal antibody K 1 that reacts with mesothelin present on mesotheliomas and ovarian cancers
NG Ordonez (1997)
10.1007/978-94-011-0681-8_78
Tissue Polypeptide Antigen
T. Ward (1995)
10.1046/j.1365-2559.1997.2510855.x
Prognostic value of high serum levels of CA‐125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature
E. Almudévar Bercero (1997)
10.1002/1097-0142(20001201)89:11+<2474::AID-CNCR26>3.0.CO;2-2
Early lung cancer action project
C. Henschke (2000)
10.1158/1078-0432.CCR-08-0360
Osteopontin Levels in an Asbestos-Exposed Population
E. Park (2009)
10.1002/(SICI)1097-0274(199609)30:3<241::AID-AJIM1>3.0.CO;2-1
Screening for asbestos-induced diseases in Finland.
K. Koskinen (1996)
21 - 1 And TPA as markers in MM
BE Almudevar (1997)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)
10.1002/(SICI)1097-0215(19970516)71:4<638::AID-IJC21>3.0.CO;2-6
Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers
U. Brinkmann (1997)
10.1016/S0169-5002(01)00294-X
Computed tomography screening for lung cancer in asbestos-exposed workers.
M. Tiitola (2002)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
10.18926/AMO/31316
The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
M. Marukawa (1998)
10.1002/1097-0142(19841115)54:10<2195::AID-CNCR2820541021>3.0.CO;2-L
Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma
B. Chiu (1984)
10.1093/ACPROF:OSO/9780195149616.001.0001
Cancer epidemiology and prevention.
D. Schottenfeld (2006)
10.1080/152873902760125354
ASBESTOS BURDEN IN TWO CASES OF MESOTHELIOMA WHERE THE WORK HISTORY INCLUDED MANUFACTURING OF CIGARETTE FILTERS
R. Dodson (2002)
Cyfra 21-1 and TPA as markers in malignant mesothelioma.
J. Bonfrer (1997)
10.1093/CARCIN/21.5.1023
mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats.
H. Sandhu (2000)
10.1378/CHEST.94.5.1037
Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.
T. Pettersson (1988)
10.1097/00008469-199110000-00011
Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations.
E. Pluygers (1991)
10.1016/0169-5002(94)92177-6
The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers.
G. Omenn (1994)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1097/00043764-199006000-00002
An historical prospective mortality study of the Sarnia Division of Dow Chemical Canada Inc., Sarnia, Ontario (1950-1984).
R. Egedahl (1989)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma.
J. Roboz (1985)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1016/S0954-6111(98)90010-5
Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer.
M. Cremades (1998)
10.1080/14774003.2005.11667666
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
10.1136/thorax.57.2.187-a
Statement on malignant mesothelioma in the UK
M. Robinson (2002)
10.1289/EHP.02110703
Characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC 11 September 2001.
P. Lioy (2002)
10.1002/0471732877.EMD269
Computed Tomography Screening
D. Brenner (2006)



This paper is referenced by
INFLUENCE OF PHYSICOCHEMICAL PROPERTIES OF SILVER NANOPARTICLES ON MAST CELL AND MACROPHAGE UPTAKE AND ACTVATION: ROLE OF SCAVENGER RECEPTOR B1
Abdullah A. Aldossari (2018)
10.1097/PAS.0b013e3182910c82
Diffuse Intrapulmonary Malignant Mesothelioma Masquerading as Interstitial Lung Disease: A Distinctive Variant of Mesothelioma
B. Larsen (2013)
10.1088/1752-7155/10/4/046001
Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
K. Lamote (2016)
10.1371/journal.pone.0014110
Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib
G. Pinton (2010)
10.1002/9781118990957.CH18
Mesothelioma: Screening in the modern age
Joanna Sesti (2018)
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.13070/MM.EN.5.1456
Tumor Markers Currently Utilized in Cancer Care
G. Romano (2015)
10.5430/JHA.V3N4P9
What can population-based physician billing data tell us about the prevalence, costs and disorders associated with different types of cancers based on the 16 years prevalence of cancer diagnosis?
J. Lui (2014)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.1158/1055-9965.EPI-13-0737
Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma—A Hypothesis
K. Lamote (2014)
10.18632/oncotarget.25237
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma
Stefania Augeri (2018)
10.1371/journal.pone.0026722
An In Vivo Platform for Tumor Biomarker Assessment
E. Servais (2011)
10.1371/journal.pone.0046091
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
10.1038/s41598-018-32315-3
Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
G. Johnen (2018)
10.1016/J.TIV.2014.10.008
Influence of physicochemical properties of silver nanoparticles on mast cell activation and degranulation.
A. A. Aldossari (2015)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1016/j.jmb.2012.06.021
Life's simple measures: unlocking the proteome.
E. Brody (2012)
10.1183/09031936.00040911
A breath test for malignant mesothelioma using an electronic nose
Elaine. Chapman (2011)
10.1517/17530059.2012.676042
Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.
G. Pinton (2012)
10.1007/s11604-010-0462-9
Malignant pleural mesothelioma detected by spontaneous pneumothorax
Akari Makidono (2010)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1007/s10147-011-0368-2
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy
S. Hasegawa (2011)
10.4103/1742-6413.99170
Parakeratotic-like cells in effusions — A clue to diagnosis of malignant mesothelioma
L. Gao (2012)
10.1586/17476348.2013.838016
Advances in the management of pleural disease
J. Corcoran (2013)
10.1016/J.EJCDT.2013.10.004
Role of fibulin-3 in the diagnosis of malignant mesothelioma
M. Agha (2014)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.5772/53397
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
10.1136/jim-2017-000628
Biological responses to asbestos inhalation and pathogenesis of asbestos-related benign and malignant disease
Eduardo Solbes (2018)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar